Q1 EPS Estimate for Bicycle Therapeutics Reduced by Analyst

Bicycle Therapeutics plc (NASDAQ:BCYC) – Research analysts at Leerink Partnrs lowered their Q1 2025 earnings estimates for shares of Bicycle Therapeutics in a report released on Tuesday, February 25th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of ($0.85) per share for the quarter, down from their prior estimate of ($0.84). The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share. Leerink Partnrs also issued estimates for Bicycle Therapeutics’ Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.89) EPS and FY2025 earnings at ($3.46) EPS.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.47 million. During the same quarter in the previous year, the business posted ($1.16) EPS. The company’s quarterly revenue was down 30.2% on a year-over-year basis.

BCYC has been the topic of a number of other research reports. Stephens restated an “equal weight” rating and set a $15.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. JMP Securities dropped their price target on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research note on Wednesday, December 18th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday. Finally, B. Riley lowered their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.14.

Bicycle Therapeutics Trading Down 2.6 %

Shares of BCYC stock opened at $11.03 on Friday. Bicycle Therapeutics has a 12 month low of $10.91 and a 12 month high of $28.67. The stock has a market cap of $761.62 million, a PE ratio of -3.35 and a beta of 0.93. The company’s fifty day moving average price is $13.35 and its 200-day moving average price is $19.46.

Insiders Place Their Bets

In other news, Director Bros. Advisors Lp Baker bought 500,000 shares of Bicycle Therapeutics stock in a transaction dated Monday, December 16th. The shares were purchased at an average cost of $15.34 per share, with a total value of $7,670,000.00. Following the completion of the acquisition, the director now owns 9,995,274 shares of the company’s stock, valued at $153,327,503.16. This trade represents a 5.27 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Alistair Milnes sold 4,578 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $64,504.02. Following the transaction, the chief operating officer now owns 100,724 shares of the company’s stock, valued at $1,419,201.16. This represents a 4.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,677 shares of company stock worth $392,413 over the last quarter. 8.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Assetmark Inc. bought a new stake in shares of Bicycle Therapeutics during the 3rd quarter worth approximately $34,000. Barclays PLC raised its position in Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company’s stock valued at $37,000 after purchasing an additional 2,345 shares in the last quarter. Avior Wealth Management LLC bought a new stake in Bicycle Therapeutics during the 4th quarter valued at $57,000. China Universal Asset Management Co. Ltd. raised its position in Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after purchasing an additional 2,918 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after purchasing an additional 1,782 shares in the last quarter. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.